Comprehensive evaluation of the effects of enalapril on matrix metalloproteinases levels in hypertension

Cardiovascular Drugs and Therapy

Volumn 26, Issue 6, 2012, Pages 511-519

  Fontana, Vanessa ^a   Silva, Pamela S ^b   Izidoro Toledo, Tatiane C ^a   Biagi, Celso ^c   Oliveira, Eduardo B ^a   Gerlach, Raquel F ^d   Tanus Santos, Jose E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c Santa Casa of Aracatuba   (Brazil)

^d Disciplines of Genetics and Molecular Biology   (Brazil)

Author keywords

ACE inhibitors; Enalapril; Hypertension; Matrix metalloproteinases

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; PHORBOL 13 ACETATE 12 MYRISTATE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; FLUOROMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPERTENSION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; ZYMOGRAPHY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CELL LINE; ENALAPRIL; ENALAPRILAT; FEMALE; HUMANS; HYPERTENSION; MALE; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 84876412031     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-012-6420-2     Document Type: Article

References (39)

1. Hanif K, Bid HK, Konwar R. Reinventing the ace inhibitors: some old and new implications of ace inhibition. Hypertens Res. 2010; 33:11-21.
2. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensinconverting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med. 2000;342:145-53.
3. Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized perindopril and remodeling in elderly with acute myocardial infarction (preami) study. Arch InternMed. 2006;166:659-66.
4. Asmar RG, Pannier B, Santoni JP, et al. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation. 1988; 78:941-50.
5. Ghiadoni L, Magagna A, Versari D, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension. 2003;41:1281-6.
6. Ong KT, Delerme S, Pannier B, et al. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients. J Hypertens. 2011;29:1034-42.
7. Castro MM, Tanus-Santos JE, Gerlach RF. Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension. Pharmacol Res. 2011;64:567-72.
8. Guimaraes DA, Rizzi E, Ceron CS, et al. Doxycycline dosedependently inhibits mmp-2-mediated vascular changes in 2k1c hypertension. Basic Clin Pharmacol Toxicol. 2011;108:318-25.
9. Rizzi E, Castro MM, Prado CM, et al. Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. J Card Fail. 2010;16:599-608.
10. Castro MM, Rizzi E, Prado CM, et al. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol. 2010;29:194-201.
11. Fontana V, Silva PS, Belo VA, et al. Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target. Basic Clin Pharmacol Toxicol. 2011;109:130-7.
12. Fontana V, Silva PS, Gerlach RF, Tanus-Santos JE. Circulating matrix metalloproteinases and their inhibitors in hypertension. Clin Chim Acta. 2012;413:656-62.
13. Yamamoto D, Takai S, Miyazaki M. Inhibitory profiles of captopril on matrix metalloproteinase-9 activity. Eur J Pharmacol. 2008;588:277-9.
14. Yamamoto D, Takai S, Hirahara I, Kusano E. Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy. Clin Chim Acta. 2010;411:762-4.
15. Yamamoto D, Takai S, Jin D, et al. Molecular mechanism of imidapril for cardiovascular protection via inhibition of mmp-9. J Mol Cell Cardiol. 2007;43:670-6.
16. Yamamoto D, Takai S, Miyazaki M. Prediction of interaction mode between a typical ace inhibitor and mmp-9 active site. Biochem Biophys Res Commun. 2007;354:981-4.
17. Sorbi D, Fadly M, Hicks R, Alexander S, Arbeit L. Captopril inhibits the 72 kda and 92 kda matrix metalloproteinases. Kidney Int. 1993;44:1266-72.
18. Reinhardt D, Sigusch HH, Hensse J, et al. Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (mmp) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ace inhibitors on mmp. Heart. 2002;88:525-30.
19. Kojima C, Ino J, Ishii H, Nitta K, Yoshida M. Mmp-9 inhibition by ace inhibitor reduces oxidized ldl-mediated foam-cell formation. J Atheroscler Thromb. 2010;17:97-105.
20. Ceron CS, Castro MM, Rizzi E, et al. Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br J Pharmacol. 2010;160:77-87.
21. Marcal DM, Rizzi E, Martins-Oliveira A, et al. Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension. Naunyn Schmiedebergs Arch Pharmacol. 2011;383:35-44.
22. MartinezML, CastroMM, Rizzi E, et al. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. Eur J Pharmacol. 2008;591:224-30.
23. Izidoro-Toledo TC, Guimaraes DA, Belo VA, Gerlach RF, Tanus- Santos JE. Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells. Naunyn Schmiedebergs Arch Pharmacol. 2011;383:547-54.
24. Dias Jr. CA, Neto-Neves EM, Montenegro MF, Tanus-Santos JE. Losartan exerts no protective effects against acute pulmonary embolism-induced hemodynamic changes. Naunyn Schmiedebergs Arch Pharmacol. 2012;385:211-7.
25. Montenegro MF, Pessa LR, Tanus-Santos JE. Isoflavone genistein inhibits the angiotensin-converting enzyme and alters the vascular responses to angiotensin i and bradykinin. Eur J Pharmacol. 2009;607:173-7.
26. Gerlach RF, Demacq C, Jung K, Tanus-Santos JE. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (mmp)-9 levels in serum versus plasma. Clin Biochem. 2007;40:119-23.
27. Gerlach RF, Meschiari CA, Marcaccini AM, et al. Positive correlations between serum and plasma matrix metalloproteinase (mmp)-2 or mmp-9 levels in disease conditions. Clin Chem Lab Med. 2009;47:888-91.
28. Fudala R, Ranjan AP, Mukerjee A, et al. Fluorescence detection of mmp-9. I. Mmp-9 selectively cleaves lys-gly-pro-arg-ser-leu-sergly- lys peptide. Curr Pharm Biotechnol. 2011;12:834-8.
29. Wellings DA, Atherton E. Standard fmoc protocols. Methods Enzymol. 1997;289:44-67.
30. Onal IK, Altun B, Onal ED, et al. Serum levels of mmp-9 and timp-1 in primary hypertension and effect of antihypertensive treatment. Eur J Intern Med. 2009;20:369-72.
31. Schieffer B, Bunte C, Witte J, et al. Comparative effects of at1- antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol. 2004;44:362-8.
32. Souza-Tarla CD, Uzuelli JA, Machado AA, Gerlach RF, Tanus- Santos JE. Methodological issues affecting the determination of plasma matrix metalloproteinase (mmp)-2 and mmp-9 activities. Clin Biochem. 2005;38:410-4.
33. Jung K, Gerlach RF, Tanus-Santos JE. Preanalytical pitfalls of blood sampling to measure true circulating matrix metalloproteinase 9 and tissue inhibitors of matrix metalloproteinases. Clin Chim Acta. 2006;373:180-1. author reply 2.
34. Souza-Costa DC, Sandrim VC, Lopes LF, et al. Anti-inflammatory effects of atorvastatin: modulation by the t-786c polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis. 2007;193:438-44.
35. Derosa G, Maffioli P, Ferrari I, et al. Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. Hypertens Res. 2011;34:145-51.
36. Takai S, Yamamoto D, Jin D, et al. Inhibition of matrix metalloproteinase-9 activity by lisinopril after myocardial infarction in hamsters. Eur J Pharmacol. 2007;568:231-3.
37. Efsen E, Saermark T, Hansen A, Bruun E, Brynskov J. Ramiprilate inhibits functional matrix metalloproteinase activity in crohn's disease fistulas. Basic Clin Pharmacol Toxicol. 2011;109:208-16.
38. Yamamoto D, Takai S. Pharmacological implications of mmp-9 inhibition by ace inhibitors. Curr Med Chem. 2009;16:1349-54.
39. Sakata Y, Yamamoto K, Mano T, et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensinconverting enzyme inhibitor. Circulation. 2004;109:2143-9.